Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for LEGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 168.05M
March 31, 2026 -1.204M
December 31, 2025 -0.6485M
September 30, 2025 0.6715M
June 30, 2025 -0.9908M
March 31, 2025 0.667M
December 31, 2024 -0.333M
September 30, 2024 4.245M
June 30, 2024 0.955M
March 31, 2024 0.831M
December 31, 2023 0.925M
September 30, 2023 0.961M
June 30, 2023 789.89M
March 31, 2023 -0.286M
Date Value
December 31, 2022 -0.783M
September 30, 2022
June 30, 2022
March 31, 2022 0.025M
December 31, 2021 323.56M
September 30, 2021 1.143M
June 30, 2021 301.75M
March 31, 2021 0.2066M
December 31, 2020 1.723M
September 30, 2020 9.663M
June 30, 2020 459.80M
March 31, 2020 148.76M
December 31, 2019 -6.68M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
AbbVie, Inc. -5.054B
Dianthus Therapeutics, Inc. 10.38M
Gilead Sciences, Inc. 2.344B
Ironwood Pharmaceuticals, Inc. -199.70M
Arbutus Biopharma Corp. 3.079M